Enduro Genetics lands $12.4M Series A to expand platform and commercialize

In Denmark, Enduro Genetics – the synthetic biology startup transforming biomanufacturing by “addicting” cells to high production – has raised €12 million in Series A funding from Supernova Invest, NOON Ventures and Sandwater. The funding will be used to expand Enduro’s platform and scale commercialization.

Enduro’s patented “synthetic addiction” technology integrates a genetic plug-in into the microbial production host, coupling each cell’s productivity to its health and growth. This ensures that only high-producing cells can survive and thrive, effectively eliminating non-productive cells from the population. By maintaining a stable and productive microbial community, Enduro Sense unlocks the full potential of industrial biomanufacturing, enabling consistent, scalable, and cost-efficient production.

Enduro is commercializing its technology at a pivotal time when industries are embracing biomanufacturing to decarbonize and create sustainable alternatives to fossil-based products, such as bio-based fuels, bioplastics, specialty chemicals, alternative proteins, and pharmaceuticals.

The new funding takes the total raised by Enduro to €18 million including grants from the BioInnovation Institute and the European Innovation Council accelerator grant, and will be used to expand Enduro’s technology platform and accelerate commercialization.